World Markets

Merck KGaA-Pfizer to terminate late-stage ovarian cancer treatment study

Reuters

Dec 21 () - Pfizer Inc and Merck KGaA said on Friday they were terminating a late-stage study for a drug to treat a form of ovarian cancer in previously untreated patients.

The results from the study showed the treatment would not achieve superiority in achieving main goal of progression-free survival.

OCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">

Dec 21 () - Pfizer Inc and Merck KGaA said on Friday they were terminating a late-stage study for a drug to treat a form of ovarian cancer in previously untreated patients.

The results from the study showed the treatment would not achieve superiority in achieving main goal of progression-free survival.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

Stocks Economy

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More